Current status in cancer cell reprogramming and its clinical implications


Izgi K., CANATAN H., Iskender B.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.143, no.3, pp.371-383, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 143 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.1007/s00432-016-2258-5
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.371-383
  • Keywords: Reprogramming, Cancer, Induced pluripotent stem cells, Pluripotency, Epigenetics, PLURIPOTENT STEM-CELLS, MOUSE SOMATIC-CELLS, C-MYC, HUMAN FIBROBLASTS, INITIATING CELLS, PROSTATE-CANCER, POOR-PROGNOSIS, SIGNALING PATHWAYS, EPIGENETIC MEMORY, ORIGIN INFLUENCES

Abstract

The technology of reprogramming a terminally differentiated cell to an embryonic-like state uncovered the possibility of reprogramming a malignant cell back to a more manageable stem cell-like state. Since the current cancer models suffer from reflecting heterogeneous tumour structure and limited to express the late-stage markers, the induced pluripotent stem cell (iPSC) technology could provide an alternative model to recapitulate the early stages of cancer. Generation of iPSCs from cancer cells could offer a tool for understanding the mechanisms of tumour initiation-progression in vitro, a platform for studying tumour heterogeneity and origin of cancer stem cells and a source for cancer type-specific drug discovery studies.